Business Context and Reporting Period
China SXT Pharmaceuticals, Inc. filed this Form 6-K for October 2026, reporting a proposed private placement and its termination. The filing is a transaction update, not a period-end financial report.
Proposed Offering and Outcome
- On October 7, 2026, the Company entered into a Securities Purchase Agreement with non-U.S. persons for a private placement of 3,000,000 Class A ordinary shares and warrants to purchase another 3,000,000 Class A ordinary shares.
- Each warrant was to be exercisable for one share at $1.00 per share. The stated gross proceeds from the offering would have been $3 million.
- On October 8, 2026, the parties agreed to terminate the offering before closing. No shares or warrants were issued, and the agreement and related obligations were terminated. The Company therefore did not receive the proposed offering proceeds.
- The securities were to be issued in reliance on Regulation S; purchasers represented that they were not U.S. persons and were not acquiring securities for the account or benefit of a U.S. person.
Financial Metrics and Comparison
The filing provides no revenue, profit, cash flow, margin, debt, or liquidity figures, and no comparison with a prior period. It does not provide a clear value for any operating or balance-sheet metric.
Outlook, Risks, and Unusual Items
The filing gives no guidance or outlook. The material development is the cancellation of the proposed financing before closing; the planned $3 million gross proceeds and potential share and warrant issuance did not occur. The filing does not state why the parties terminated the offering.
Key Facts for Investors to Verify
- Review Exhibits 4.1, 10.1, and 10.2, which contain forms of the warrant, Securities Purchase Agreement, and Termination Agreement.
- Confirm that the offering was terminated before closing and that no shares or warrants were issued.
- Check subsequent filings for any replacement financing, completed issuance, or further details about the termination.